文献速递血管炎

肉芽肿性多血管炎诱导失败:全国性病例对照研究 of 危险因素与结局

Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该全国性回顾性病例对照研究纳入2006至2021年间51例诱导失败的肉芽肿性多血管炎(GPA)患者,每例随机匹配3例对照。静脉环磷酰胺诱导失败者更多见PR3-ANCA阳性、复发性疾病和眶部肿块;利妥昔单抗诱导后疾病进展者更多见肾脏受累和肾功能衰竭。挽救治疗后6个月35例(69%)达缓解。

要点

  • 静脉环磷酰胺诱导失败者更多见PR3-ANCA阳性(93% vs 70%)、复发性疾病(41% vs 7%)和眶部肿块(15% vs 0%)。
  • 利妥昔单抗诱导后进展者更多见肾脏受累(67% vs 25%)和血清肌酐>100 µmol/l(42% vs 8%)。
  • 最常见的挽救治疗为静脉环磷酰胺与利妥昔单抗互换,有效率为21/29(72%)。

核心结论

  • 在诱导失败患者中,GPA特征、挽救治疗及其疗效因诱导治疗方案和失败模式而异。

研究设计与样本

  • 全国性回顾性病例对照研究,纳入2006至2021年间51例诱导失败的GPA患者(29男22女),每例随机匹配3例对照,按年龄、性别和诱导治疗匹配。

主要发现

  • 诱导治疗时中位年龄49岁,27例接受静脉环磷酰胺诱导,24例接受利妥昔单抗诱导。
  • 静脉环磷酰胺诱导失败者较对照更常见PR3-ANCA(93% vs 70%,P=0.02)、复发性疾病(41% vs 7%,P<0.001)和眶部肿块(15% vs 0%,P<0.01)。
  • 利妥昔单抗诱导后疾病进展者较对照更常见肾脏受累(67% vs 25%,P=0.02)和肾功能衰竭(血清肌酐>100 µmol/l:42% vs 8%,P=0.02)。
  • 挽救治疗后6个月35例(69%)达缓解;静脉环磷酰胺与利妥昔单抗互换有效率为21/29(72%)。
  • 对静脉环磷酰胺反应不佳者9例(50%)达缓解;利妥昔单抗诱导后进展者中,接受静脉环磷酰胺(联合或不联合免疫调节治疗)者4例(100%)达缓解,仅加用免疫调节治疗者3例(50%)达缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify characteristics of granulomatosis with polyangiitis (GPA) associated with induction failure, describe salvage therapies and their efficacy. METHODS: We conducted a nationwide retrospective case-control study of GPA with induction failure between 2006 and 2021. Each patient with induction failure was randomly paired to three controls matched for age, sex and induction treatment. RESULTS: We included 51 patients with GPA and induction failure (29 men and 22 women). At induction therapy, median age was 49 years. Twenty-seven patients received intravenous cyclophosphamide (ivCYC) and 24 rituximab (RTX) as induction therapy. Patients with ivCYC induction failure more frequently had PR3-ANCA (93% vs 70%, P = 0.02), relapsing disease (41% vs 7%, P < 0.001) and orbital mass (15% vs 0%, P < 0.01) compared with controls. Patients with disease progression despite RTX induction therapy more frequently had renal involvement (67% vs 25%, P = 0.02) with renal failure (serum creatinine >100 µmol/l in 42% vs 8%, P = 0.02) compared with controls. After salvage therapy, remission was achieved at 6 months in 35 (69%) patients. The most frequent salvage therapy was switching from ivCYC to RTX (or vice versa), showing an efficacy in 21/29 (72%). Remission was achieved in nine (50%) patients with inappropriate response to ivCYC, while in patients with progression after RTX induction, remission was achieved in four (100%) who received ivCYC (with or without immunomodulatory therapy), but only in three (50%) after adding immunomodulatory therapy alone. CONCLUSION: In patients with induction failure, characteristics of GPA, salvage therapies and their efficacy vary according to induction therapy and failure modality.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sorin B, Iudici M, Guerry MJ, et al. Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes. Rheumatology (Oxford). 2023. PMID: 36847447. doi:10.1093/rheumatology/kead098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。